IJGC conversations

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Mariana Scaranti to discuss ESMO 2025 Highlights: Top Studies In Gynecologic Oncology.

 

Mariana Scaranti, MD, is a Brazilian medical oncologist dedicated to gynecologic oncology. She practices at Hospital 9 de Julho in São Paulo and is the National Lead for Gynecologic Oncology at Rede Américas, Brazil. She serves as Research Director of Grupo EVA, the Brazilian Gynecologic Oncology Group, and is a member of the Gynecologic Tumors Committee of the Brazilian Society of Clinical Oncology (SBOC). She previously trained as a fellow at The Royal Marsden NHS Foundation Trust in London

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Nicole Concin to discuss ESGO-ESTRO-ESP 2025 Endometrial Cancer Guidelines.

 

Professor Concin serves as the Chair of the Department of Gynaecology and Gynaecological Oncology and as Director of the Department of Obstetrics and Gynaecology at the Medical University of Vienna. She is President of the Austrian Network of Gynaecologic Oncology (AGO Austria), Executive Committee member of
the European Society of Gynaecological Oncology (ESGO), immediate Past-President of the ESGO, Board of Directors member of GCIG Gynaecologic Cancer InterGroup (GCIG), education faculty member for gynaecological cancer of the European Society of Medical Oncology (ESMO) and Board member of the International Federation of Gynaecology and Obstetrics (FIGO) Committee on Women’s Cancer.

Professor Concin’s clinical, research and teaching focus is gynaecological oncology. She has led multiple translational and clinical research projects worldwide and provided her expertise in >100 international clinical trials in gynaecological oncology, several of which she served as Principal or Global Coordinating Investigator. She has authored >150 research articles inhighly ranked peer-reviewed Journals. Her most cited article is the European multidisciplinary guidelines for the management of patients with endometrial carcinoma (Concin N. et al, IJGC Dec 2020; >1300 citations). In recognition of Professor Concin’s ability and achievements, she has received multiple grants and awards including the award of the Austrian Society for Cancer Aid, i.e. the Univ. Prof. DDr. Karl Fellinger Award. Her recent article in Lancet Oncology, “ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: Update 2025,” presents the latest revision of the guidelines, building upon the previous version published in 2021.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Drs. Cristina Taliento and Giuseppe Vizzielli to discuss ctDNA & diagnosis of ovarian cancer.

 

Cristina Taliento is a gynecologist and PhD candidate in a joint PhD program at the University Hospital of Ferrara, Italy, and KU Leuven, Belgium, associated with the International Ovarian Tumour Analysis (IOTA) Group. She completed a Research Fellowship at the European Institute of Oncology in Milan. She recently started her Fellowship Training in Gynecologic Oncology at the University Hospital of Heidelberg, Germany. Her PhD research focuses on clinical and translational studies in the diagnosis and management of adnexal tumors, with a particular interest in circulating tumor DNA in ovarian cancer.

 

Giuseppe Vizzielli is an associate professor of gynecology and obstetrics at the Department of Medicine, University of Udine, and Chief of the Gynecologic Oncology Unit at University Hospital of Udine, Italy. He completed his Ph.D. studies in molecular pathology in gynaecological oncology at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma. He is a member of the European Society of Gynaecological Oncology (ESGO) and a member of the Italian Society of Gynaecological Endoscopy (SEGI), affiliated with the ESGE. He was the principal investigator of the national research project,  Longitudinal genomic and transcriptomic analysis on ovarian cancer organoids. He serves as an official reviewer of many indexed international journals as well as Lancet Oncology, the International Journal of Gynecological Cancer, the European Journal of Surgical Oncology, World Journal of Surgical Oncology, European Journal of Obstetrics and Gynecology and Reproductive Biology, Archives of Gynecology and Obstetrics, and BMC Cancer, and he is an associate editor of BMC Cancer, Cancers and the World Journal of Surgical Oncology. His recent publication in IJGC focuses on Circulating tumor DNA in the diagnosis of ovarian cancer.

In this episode of the IJGC conversations 2025 December Editor's Choice, Editorial Fellow Itziar Villagrá, Joannie Neveu, and Mathilde Del discusses the contents of the 2025 December issue of IJGC.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Bradley Monk to discuss ctDNA: Results from CALLA Trial.

 

Bradley Monk, MD, FACOG, FACS is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute and medical director of the Late-Stage Clinical Research Program. He provides care to patients at the FCS West Palm Beach location.
Dr. Monk has extensive leadership experience in practice-changing clinical research and the development of clinical research programs in community oncology settings. His research special interests are primarily focused on the prevention and treatment of gynecologic cancers. As a principal investigator, Dr. Monk has been involved in numerous groundbreaking studies throughout his career.
Dr. Monk is a co-founder of the GOG-Partners (GOG-P) Foundation® (GOG-F), a nonprofit organization committed to advancing clinical and scientific research in the field of gynecologic malignancies. The organization was instrumental in establishing a national gynecologic clinical trials network. He has presented his findings at hundreds of national and international forums and authored more than 400 peer-reviewed articles and more than 35 book chapters focused on the prevention and treatment of gynecologic malignancies and patient reported outcomes. Dr. Monk is a past recipient of the esteemed Ernst Wertheim Award for his research in cervical cancer.
Prior to joining FCS in 2024, Dr. Monk served as director and principal investigator for HonorHealth at the Virginia G. Piper Cancer Center in Scottsdale, Arizona, where he also served as the site research leader for Sarah Cannon Research Institute. Among his numerous academic appointments, he most recently served as a professor on the Clinical Scholar Track at the University of Arizona College of Medicine.